Scott A. Biller - Concepedia

Author

Scott A. Biller

Also Known As

Biller, Scott A., Biller, Scott Adams, S A Biller, S. A. BILLER, S. A. Biller, S. Biller, SCOTT A. BILLER, Scott A Biller, Scott A. Biller, Scott Biller

121

Publications

10.2K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Agios Pharmaceuticals (United States)Bristol-Myers Squibb (Germany)Institut Gustave Roussy Memorial Sloan Kettering Cancer Center

About

Scott A. Biller is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	31	5.2K
2	Biochemistry	22	26	2.4K
3	Natural Sciences	19	21	1.2K
4	Engineering	9	9	410
5	Health Sciences	2	2	348

Scott A. Biller

Publications

10K

Citations

H-Index

Page 1

	Year	Citations
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells Dan Rohle, Janeta Popovici-Müller, Nicolaos Palaskas, Science Cancer BiologyGliomaTumor BiologyCancer MetabolismRadiation Oncology	2013	1.1K
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation Fang Wang, Jeremy Travins, Byron DeLaBarre, Science	2013	789
Electrophilic properties of itaconate and derivatives regulate the IκBζ–ATF3 inflammatory axis Monika Bambousková, Laurent Gorvel, Vicky Lampropoulou, Nature InflammationCytokineInflammatory DiseaseSignal TransductionImmunology	2018	695
Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes David J. Augeri, Jeffrey A. Robl, David A. Betebenner, Journal of Medicinal Chemistry	2005	617
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl, Journal of Medicinal Chemistry Metabolic SyndromeDiabetes ManagementBiochemistryMedicineDiabetes	2008	612
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations Katharine Yen, Jeremy Travins, Fang Wang, Cancer Discovery	2017	444
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers Janeta Popovici-Müller, René M. Lemieux, Erin Artin, ACS Medicinal Chemistry Letters Idh1 Mutant CancersSomatic Point MutationsSomatic VariantOncogenic AgentMedicine	2018	422
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats Song‐Ping Han, Deborah Hagan, Joseph R. Taylor, Diabetes	2008	416
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis Katya Marjon, Michael J. Cameron, Phong Quang, Cell Reports	2016	415
Free-radical cyclization of bromo acetals. Use in the construction of bicyclic acetals and lactones Gilbert Stork, Robert Mook, Scott A. Biller, Journal of the American Chemical Society HeterocyclicChemical AnalysisAltmetric Attention ScoreChemometricsOrganic Chemistry	1983	274

Page 1